Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Kurveundersøgelse af Entrectinib (RXDX-101) til behandling af patienter med solide tumorer, der rummer NTRK 1/2/3 (Trk A/B/C), ROS1 eller ALK genrearrangementer (fusioner) (STARTRK-2)

16. november 2026 opdateret af: Hoffmann-La Roche

Et åbent, multicenter, globalt fase 2-basketstudie af entrectinib til behandling af patienter med lokalt avancerede eller metastatiske solide tumorer, der rummer NTRK1/2/3-, ROS1- eller ALK-genomlægninger

This is an open-label, multicenter, global Phase 2 basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors that harbor an NTRK1/2/3, ROS1, or ALK gene fusion. Patients will be assigned to different baskets according to tumor type and gene fusion.

Studieoversigt

Status

Afsluttet

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

534

Fase

  • Fase 2

Udvidet adgang

Ikke længere tilgængelig uden for det kliniske forsøg. Se udvidet adgangsregistrering.

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • New South Wales
      • Liverpool, New South Wales, Australien, 2170
        • Liverpool Hospital
      • Newcastle, New South Wales, Australien, 2305
        • Newcastle Private Hospital
    • South Australia
      • Bedford Park, South Australia, Australien, 5042
        • Flinders Medical Centre
    • Victoria
      • Heidelberg, Victoria, Australien, 3084
        • Austin Health
      • Edegem, Belgien, 2650
        • Pharmacy
      • Cambridge, Det Forenede Kongerige, CB2 0QQ
        • Addenbrookes Hospital
      • London, Det Forenede Kongerige, W1G 6AD
        • Sarah Cannon Research Institute
      • Manchester, Det Forenede Kongerige, M20 4BX
        • The Christie
    • Arizona
      • Phoenix, Arizona, Forenede Stater, 85054
        • Mayo Clinic
      • Phoenix, Arizona, Forenede Stater, 85013
        • Dignity Health St Joseph's Hospital and Medical Center
    • California
      • Duarte, California, Forenede Stater, 91010
        • City of Hope Cancer Center
      • Duarte, California, Forenede Stater, 91010
        • City of Hope Duarte - Comprehensive Cancer Center, Investigational Drug Services
      • La Jolla, California, Forenede Stater, 92037
        • Scripps Clinic
      • La Jolla, California, Forenede Stater, 92093
        • University of California San Diego Moores Cancer Center
      • Los Angeles, California, Forenede Stater, 90027
        • Southern California Kaiser Permanente
      • Orange, California, Forenede Stater, 92868
        • Univ Of California Irvine College Of Medicine
      • San Francisco, California, Forenede Stater, 94158
        • UCSF Mission Bay
      • San Francisco, California, Forenede Stater, 94115
        • UCSF Mount Zion Medical Ctr
      • Santa Monica, California, Forenede Stater, 90403
        • Sarcoma Oncology Center
      • Santa Monica, California, Forenede Stater, 90403
        • Sarcoma Oncology Research Center LLC
    • Colorado
      • Aurora, Colorado, Forenede Stater, 80045
        • University of Colorado Cancer Center
    • Connecticut
      • New Haven, Connecticut, Forenede Stater, 6519
        • Yale University
    • District of Columbia
      • Washington D.C., District of Columbia, Forenede Stater, 20007
        • Georgetown University Medical Center Lombardi Cancer Center
    • Florida
      • Sarasota, Florida, Forenede Stater, 34232
        • Florida Cancer Specialists - Sarasota
      • Tampa, Florida, Forenede Stater, 33612-9497
        • Moffitt Cancer Center
      • Tampa, Florida, Forenede Stater, 33612-9497
        • H. Lee Moffitt Cancer Center and Research Inst.
    • Georgia
      • Athens, Georgia, Forenede Stater, 30607
        • University Cancer & Blood Center, LLC
      • Atlanta, Georgia, Forenede Stater, 30322
        • Winship Cancer Institute
      • Newnan, Georgia, Forenede Stater, 30265
        • Southeastern Regional Medical Center, Inc.
    • Illinois
      • Chicago, Illinois, Forenede Stater, 60611
        • Northwestern University
      • Park Ridge, Illinois, Forenede Stater, 60068
        • Advocate Medical Group - Park Ridge, Luther Lane - Oncology
      • Zion, Illinois, Forenede Stater, 60099
        • Midwestern Regional Medical Center
    • Maryland
      • Baltimore, Maryland, Forenede Stater, 21237
        • Weinberg Cancer Institution at Franklin Square
    • Massachusetts
      • Boston, Massachusetts, Forenede Stater, 02215
        • Beth Israel Deaconess Medical Center
      • Boston, Massachusetts, Forenede Stater, 02114
        • Massachusetts General Hospital
      • Boston, Massachusetts, Forenede Stater, 02215
        • Dana Farber Cancer Institute
      • Boston, Massachusetts, Forenede Stater, 02114
        • Massachusetts General Hosp CAR
    • Michigan
      • Detroit, Michigan, Forenede Stater, 48202
        • Henry Ford Hospital
      • Detroit, Michigan, Forenede Stater, 48201
        • Karmanos Cancer Center
    • Minnesota
      • Minneapolis, Minnesota, Forenede Stater, 55455
        • Regents of the University of Minnesota
    • Missouri
      • St Louis, Missouri, Forenede Stater, 63128
        • Washington University
    • Nevada
      • Las Vegas, Nevada, Forenede Stater, 89169
        • Comprehensive Cancer Centers of Nevada (CCCN) - Central Valley
    • New York
      • East Setauket, New York, Forenede Stater, 11733
        • North Shore Hem Onc Associates
      • New York, New York, Forenede Stater, 10022
        • Memorial Sloan Kettering Cancer Center
    • North Carolina
      • Charlotte, North Carolina, Forenede Stater, 28204
        • Levine Cancer Institute
      • Charlotte, North Carolina, Forenede Stater, 28204
        • Atrium Health Levine Cancer Institute
      • Durham, North Carolina, Forenede Stater, 27710
        • Duke Cancer Institute
    • Ohio
      • Columbus, Ohio, Forenede Stater, 43210
        • Ohio State University
    • Oklahoma
      • Tulsa, Oklahoma, Forenede Stater, 74133
        • Cancer Treatment Centers of America
    • Oregon
      • Portland, Oregon, Forenede Stater, 97239-3098
        • Oregon Health & Science University
      • Portland, Oregon, Forenede Stater, 97239
        • Oregon Health & Science Univ
    • Texas
      • Dallas, Texas, Forenede Stater, 75230
        • Mary Crowley Medical Research Center
      • Temple, Texas, Forenede Stater, 76508
        • Baylor Scott & White Health
    • Virginia
      • Fairfax, Virginia, Forenede Stater, 22031
        • Virginia Cancer Specialists, PC
      • Norfolk, Virginia, Forenede Stater, 23502
        • Virginia Oncology Associates - Hampton
      • Angers, Frankrig, 49055
        • Institut de Cancerologie de l Ouest
      • Lyon, Frankrig, 69373
        • Centre Leon Berard
      • Marseille, Frankrig, 13915
        • Hôpital Nord - AP-HM Marseille#
      • Marseille, Frankrig, 13385
        • Hôpital de la Timone
      • Montpellier, Frankrig, 34090
        • Institut de Recherche en Cancérologie de Montpellier
      • Toulouse, Frankrig, 31059
        • Institut Claudius Regaud
      • Villejuif, Frankrig, 94805
        • Institut Gustave Roussy
      • Leiden, Holland, 2333 ZA
        • Leids Universitair Medisch Centrum
      • Hong Kong, Hong Kong
        • The University of Hong Kong
      • Hong Kong, Hong Kong
        • Princess Margaret Hospital
      • Kowloon, Hong Kong
        • Queen Elizabeth Hospital
      • Shatin, Hong Kong, 123456
        • The Chinese University of Hong Kong
    • Campania
      • Naples, Campania, Italien, 80131
        • Seconda Università degli Studi di Napoli
    • Lazio
      • Rome, Lazio, Italien, 128
        • Università Campus Bio-Medico di Roma
    • Lombardy
      • Milan, Lombardy, Italien, 20133
        • Fondazione IRCCS Istituto Nazionale dei Tumori
      • Milan, Lombardy, Italien, 20162
        • Azienda Socio Sanitaria Territoriale Niguarda (Ospedale Niguarda Ca' Granda)
    • Tuscany
      • Pisa, Tuscany, Italien, 56126
        • Azienda Ospedaliero Universitaria Pisana
    • Umbria
      • Perugia, Umbria, Italien, 6132
        • Azienda Ospedaliera di Perugia Ospedale S. Maria della Misericordia
    • Veneto
      • Padova, Veneto, Italien, 35128
        • IOV - Istituto Oncologico Veneto - IRCCS
      • Aichi, Japan, 464-8681
        • Aichi Cancer Center Hospital
      • Chūō, Japan, 104-0045
        • National Cancer Center Hospital
      • Hyōgo, Japan, 673-8558
        • Hyogo Cancer Center, Dept of Respiratory Medicine
      • Matsuyama, Japan, 791-0280
        • NHO Shikoku Cancer Center
      • Miyagi, Japan, 981-1293
        • Miyagi Cancer Center
      • Niigata, Japan, 951-8566
        • Niigata Cancer Center Hospital
      • Osaka, Japan, 589-8511
        • Kindai University Hospital
      • Osaka, Japan, 534-0021
        • Osaka City General Hospital
      • Shizuoka, Japan, 411-8777
        • Shizuoka Cancer Center
      • Beijing, Kina, 100142
        • Beijing Cancer Hospital
      • Guangzhou, Kina, 528400
        • Cancer Center of Guangzhou Medical University
      • Hangzhou, Kina, 310022
        • Zhejiang Cancer Hospital
      • Shanghai, Kina, 200120
        • Fudan University Shanghai Cancer Center
      • Shanghai, Kina, 200030
        • Shanghai chest hospital
      • Shenzhen, Kina, 510852
        • Shenzhen People's Hospital
    • Heilongjiang
      • Harbin, Heilongjiang, Kina, 150081
        • Harbin Medical University Cancer Hospital
    • Hubei
      • Wuhan, Hubei, Kina, 430023
        • Union Hospital Tongji Medical College Huazhong University of Science and Technology
    • Sichuan
      • Chengdu, Sichuan, Kina, 610041
        • Sichuan Cancer Hospital
      • Gliwice, Polen, 44-101
        • Centrum Onkologii-Instytut im.M.Sklodowskiej Curie
      • Późna, Polen, 60-569
        • Szpital Kliniczny Przemienienia Panskiego Uni. Medycznego im. Karola Marcinkowskiego
      • Singapore, Singapore, 119228
        • National University Hospital
      • Singapore, Singapore, 168583
        • National Cancer Centre Singapore
      • Barcelona, Spanien, 08035
        • Vall d?Hebron Institute of Oncology (VHIO), Barcelona
      • Madrid, Spanien, 28034
        • Hospital Universitario Ramon y Cajal
      • Madrid, Spanien, 28041
        • Hospital Universitario 12 de Octubre
      • Madrid, Spanien, 28046
        • Hospital Universitario La Paz
      • Madrid, Spanien, 28040
        • Hospital Universitario Clínico San Carlos
      • Málaga, Spanien, 29010
        • Hospital Clinico Universitario Virgen de la Victoria
      • Seville, Spanien, 41013
        • Hospital Universitario Virgen del Rocio
    • Madrid
      • Fuenlabrada, Madrid, Spanien, 28942
        • Centro Nacional de Investigaciones Oncológicas(CNIO)
      • Seoul, Sydkorea, 03080
        • Seoul National University Hospital
      • Seoul, Sydkorea, 06351
        • Samsung Medical Center
      • Seoul, Sydkorea, 05505
        • Asan Medical Center.
      • Seoul, Sydkorea, 120-752
        • Severance Hospital, Yonsei University Health System
      • Tainan, Taiwan, 70457
        • National Cheng Kung University Hospital
      • Taipei, Taiwan, 11217
        • Taipei Veterans General Hospital
      • Taipei, Taiwan, 00100
        • National Taiwan University Hospital
      • Berlin, Tyskland, 13125
        • Evang. Lungenklinik Berlin Klinik für Pneumologie
      • Cologne, Tyskland, 50937
        • Universitaetsklinikum Koeln
      • Göttingen, Tyskland, 37075
        • Universitaetsmedizin Goettingen
      • Heidelberg, Tyskland, 69120
        • NCT Uniklinikum Heidelberg

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Histologically- or cytologically-confirmed diagnosis of locally advanced or metastatic solid tumor that harbors an NTRK1/2/3, ROS1, or ALK gene rearrangement

  • For patients enrolled via local molecular testing, an archival or fresh tumor tissue (unless medically contraindicated) is required to be submitted for independent central molecular testing at Ignyta's CLIA laboratory post-enrollment

  • Measurable or evaluable disease

  • Patients with CNS involvement, including leptomeningeal carcinomatosis, which is either asymptomatic or previously-treated and controlled, are allowed

  • Prior anticancer therapy is allowed (excluding approved or investigational Trk, ROS1, or ALK inhibitors in patients who have tumors that harbor those respective gene rearrangements)

    - Note: prior treatment with crizotinib is permitted only in ALK- or ROS1-rearranged NSCLC patients presenting with CNS-only progression. Other ALK inhibitors are prohibited.

  • At least 2 weeks or 5 half-lives, whichever is shorter, must have elapsed after prior chemotherapy or small molecule targeted therapy

  • At least 4 weeks must have elapsed since completion of antibody-directed therapy

  • Prior radiotherapy is allowed if more than 14 days have elapsed since the end of treatment

  • Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 and minimum life expectancy of 4 weeks

  • Adequate organ function as defined per protocol

  • Ability to swallow entrectinib intact

  • Other protocol specified criteria

Exclusion Criteria:

  • Current participation in another therapeutic clinical trial

  • Prior treatment with approved or investigational Trk, ROS1, or ALK inhibitors in patients who have tumors that harbor those respective gene rearrangements

    - Note: prior treatment with crizotinib is permitted only in ALK- or ROS1-rearranged NSCLC patients presenting with CNS-only progression. Other ALK inhibitors are prohibited.

  • History of other previous cancer that would interfere with the determination of safety or efficacy

  • Familial or personal history of congenital bone disorders, or bone metabolism alterations

  • Incomplete recovery from any surgery

  • History of recent (within the past 3 months) symptomatic congestive heart failure or ejection fraction ≤50% observed during screening for the study

  • History of non-pharmacologically induced prolonged QTc interval

  • History of additional risk factors for torsades de pointes

  • Peripheral neuropathy Grade ≥ 2

  • Known active infections

  • Active gastrointestinal disease or other malabsorption syndromes

  • Known interstitial lung disease, interstitial fibrosis, or history of tyrosine kinase inhibitor-induced pneumonitis

  • Other protocol specified criteria

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Ikke-randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: NTRK1/2/3-rearranged NSCLC

Oral entrectinib (RXDX-101)

TrkA/B/C, ROS1, and ALK inhibitor

Andre navne:
  • RXDX-101
Eksperimentel: ROS1-rearranged NSCLC

Oral entrectinib (RXDX-101)

TrkA/B/C, ROS1, and ALK inhibitor

Andre navne:
  • RXDX-101
Eksperimentel: ALK- or ROS1-rearranged NSCLC

with CNS-only progression previously treated with crizotinib (NOTE: The ALK-rearranged portion of this arm is now closed to enrollment.)

Oral entrectinib (RXDX-101)

TrkA/B/C, ROS1, and ALK inhibitor

Andre navne:
  • RXDX-101
Eksperimentel: NTRK/1/2/3-rearranged mCRC

Oral entrectinib (RXDX-101)

TrkA/B/C, ROS1, and ALK inhibitor

Andre navne:
  • RXDX-101
Eksperimentel: ROS1-rearranged mCRC

Oral entrectinib (RXDX-101)

TrkA/B/C, ROS1, and ALK inhibitor

Andre navne:
  • RXDX-101
Eksperimentel: ALK-rearranged mCRC

Oral entrectinib (RXDX-101)

TrkA/B/C, ROS1, and ALK inhibitor

Andre navne:
  • RXDX-101
Eksperimentel: NTRK1/2/3-rearranged other solid tumor

Oral entrectinib (RXDX-101)

TrkA/B/C, ROS1, and ALK inhibitor

Andre navne:
  • RXDX-101
Eksperimentel: ROS1-rearranged other solid tumor

Oral entrectinib (RXDX-101)

TrkA/B/C, ROS1, and ALK inhibitor

Andre navne:
  • RXDX-101
Eksperimentel: ALK-rearranged other solid tumor

Oral entrectinib (RXDX-101)

TrkA/B/C, ROS1, and ALK inhibitor

Andre navne:
  • RXDX-101

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Objective Response Rate
Tidsramme: Approximately 24 months

Assessed by blinded independent central review (BICR) using RECIST v1.1

Approximately 24 months

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Duration of Response
Tidsramme: Approximately 24 months

Assessed by blinded independent central review (BICR) using RECIST v1.1

Approximately 24 months
Time to Response
Tidsramme: Approximately 24 months

Assessed by blinded independent central review (BICR) using RECIST v1.1

Approximately 24 months
Clinical Benefit Rate
Tidsramme: Approximately 24 months

Assessed by blinded independent central review (BICR) using RECIST v1.1

Approximately 24 months
Intracranial Tumor Response
Tidsramme: Approximately 24 months

Assessed by blinded independent central review (BICR) using RANO or RANO-BM, as applicable

Approximately 24 months
CNS Progression-free Survival
Tidsramme: Approximately 24 months

Assessed by blinded independent central review (BICR) using RANO or RANO-BM, as applicable

Approximately 24 months
Progression-free Survival
Tidsramme: Approximately 30 months

Assessed by Kaplan-Meier method

Approximately 30 months
Overall Survival
Tidsramme: Approximately 36 months

Assessed by Kaplan-Meier method

Approximately 36 months
Population PK
Tidsramme: Approximately 24 months

Assessed by Kaplan-Meier method

Approximately 24 months
Adverse Events
Tidsramme: Approximately 36 months

Type, incidence, severity, timing, seriousness, and relatedness of adverse events and laboratory abnormalities, graded by the NCI CTCAE

Approximately 36 months
Quality of Life
Tidsramme: Approximately 24 months

Assessed with the European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life Questionnaire (QLQ-C30) and the Euro-QoL Group EQ-5D. NSCLC and mCRC patients will complete the lung cancer and colorectal cancer specific modules, QLQ-LC13 and QLQ-CR29, respectively

Approximately 24 months
Bone Growth and Bone Mineral Density
Tidsramme: Approximately 30 months

Assessed with DHA scans

Approximately 30 months
Bone Biomarkers
Tidsramme: Approximately 30 months

Measured by blood

Approximately 30 months

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Efterforskere

  • Studieleder: Clinical Trials, Hoffmann-La Roche

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Generelle publikationer

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

19. november 2015

Primær færdiggørelse (Faktiske)

29. oktober 2026

Studieafslutning (Faktiske)

29. oktober 2026

Datoer for studieregistrering

Først indsendt

2. oktober 2015

Først indsendt, der opfyldte QC-kriterier

2. oktober 2015

Først opslået (Anslået)

5. oktober 2015

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

17. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

16. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • RXDX-101-02
  • 2015-003385-84 (EudraCT nummer)
  • GO40782 (Anden identifikator: Hoffman-La Roche)
  • 2023 (U.S. NIH-bevilling/kontrakt)
  • 2015 (U.S. NIH-bevilling/kontrakt)
  • 2023-505034-10-00 (Ctis)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .